Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CERStrong pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results